Nicholas Holliday and how he has combined his university role with his leadership of Excellerate Bioscience

Industry News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant Excellerate Bioscience Announces Site Relocation AI can help to speed up drug discovery — but only if we give it

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief Excellerate is involved in several pre-clinical drug discovery projects for both GPCR and non-GPCR targets Nicholas Holliday on the web LinkedIn ORCID University of Nottingham Twitter Excellerate Bio Dr.

in industry, academia and her entrepreneurial side led her to three companies, Cue Biotech , Caden Biosciences

Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences